Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | TEC | P42680 | 1/20 | 0.53 |
| ▸ | TXK | P42681 | 1/20 | 0.53 |
| ▸ | BLK | P51451 | 1/20 | 0.53 |
| ▸ | BMX | P51813 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
| ▸ | ITK | Q08881 | 1/20 | 0.53 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14915720 | 1.00 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL24374783 | 0.94 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL20281235 | 0.89 | BTK (0.62) | BTKEGFRERBB2TECTXK | |
| SCHEMBL25707138 | 0.88 | BTK (0.58) | BTKEGFRERBB2TECTXK | |
| SCHEMBL14934007 | 0.87 | BTK (0.51) | BTKEGFRERBB2TECTXK | |
| SCHEMBL18777835 | 0.87 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL14916195 | 0.87 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL14914054 | 0.87 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL14913070 | 0.87 | BTK (0.55) | BTKEGFRERBB2TECTXK | |
| SCHEMBL31158074 | 0.87 | BTK (0.55) | BTKEGFRERBB2TECTXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773639-B1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-9115152-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8946213-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2773639-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729072-B2 | Alkylated piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2014-05-20 | — | — | US | disclosed |
| WO-2013067277-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | BTK 1/4885EGFR 696/4885ERBB2 72/4885 |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | BTK 1/4885EGFR 1525/4885ERBB2 206/4885 |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | BTK 1/4885EGFR 696/4885ERBB2 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.